AUTOPROCESSING OF THE HIV-1 PROTEASE USING PURIFIED WILD-TYPE AND MUTATED FUSION PROTEINS EXPRESSED AT HIGH-LEVELS IN ESCHERICHIA-COLI

被引:71
作者
LOUIS, JM
MCDONALD, RA
NASHED, NT
WONDRAK, EM
JERINA, DM
OROSZLAN, S
MORA, PT
机构
[1] NCI, DIV CANC BIOL & DIAG, BETHESDA, MD 20892 USA
[2] NCI, FREDERICK CANC RES & DEV CTR, BASIC RES PROGRAM, ABL, FREDERICK, MD 21701 USA
来源
EUROPEAN JOURNAL OF BIOCHEMISTRY | 1991年 / 199卷 / 02期
关键词
D O I
10.1111/j.1432-1033.1991.tb16132.x
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Various constructs of the human immunodeficiency virus, type 1 (HIV-1) protease containing flanking Pol region sequences were expressed as fusion proteins with the maltose-binding protein of the malE gene of Escherichia coli. The full-length fusion proteins did not exhibit self-processing in E. coli, thereby allowing rapid purification by affinity chromatography on cross-linked amylose columns. Denaturation of the fusion protein in 5 M urea, followed by renaturation, resulted in efficient site-specific autoprocessing to release the 11-kDa protease. Rapid purification involving two column steps gave an HIV-1 protease preparation of > 95% purity (specific activity almost-equal-to 8500 pmol . min-1 . mu-g protease-1) with an overall yield of about 1 mg/l culture. Incubation of an inactive mutant protease fusion protein with the purified wild-type protease resulted in specific trans cleavage and release of the mutant protease. Analysis of products of the HIV-1 fusion proteins containing mutations at either the N- or the C-terminal protease cleavage sites indicated that blocking one of the cleavage sites influences the cleavage at the non-mutated site. Such mutated full-length and truncated protease fusion proteins possess very low levels of proteolytic activity (almost-equal-to 5 pmol . min-1 . mu-g protein-1).
引用
收藏
页码:361 / 369
页数:9
相关论文
共 28 条
  • [1] ATG VECTORS FOR REGULATED HIGH-LEVEL EXPRESSION OF CLONED GENES IN ESCHERICHIA-COLI
    AMANN, E
    BROSIUS, J
    [J]. GENE, 1985, 40 (2-3) : 183 - 190
  • [2] INHIBITION OF HIV PROTEASE ACTIVITY BY HETERODIMER FORMATION
    BABE, LM
    PICHUANTES, S
    CRAIK, CS
    [J]. BIOCHEMISTRY, 1991, 30 (01) : 106 - 111
  • [3] ISOLATION OF A T-LYMPHOTROPIC RETROVIRUS FROM A PATIENT AT RISK FOR ACQUIRED IMMUNE-DEFICIENCY SYNDROME (AIDS)
    BARRESINOUSSI, F
    CHERMANN, JC
    REY, F
    NUGEYRE, MT
    CHAMARET, S
    GRUEST, J
    DAUGUET, C
    AXLERBLIN, C
    VEZINETBRUN, F
    ROUZIOUX, C
    ROZENBAUM, W
    MONTAGNIER, L
    [J]. SCIENCE, 1983, 220 (4599) : 868 - 871
  • [4] BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
  • [5] GENETIC-LOCUS, PRIMARY STRUCTURE, AND CHEMICAL SYNTHESIS OF HUMAN IMMUNODEFICIENCY VIRUS PROTEASE
    COPELAND, TD
    OROSZLAN, S
    [J]. GENE ANALYSIS TECHNIQUES, 1988, 5 (06): : 109 - 115
  • [6] HUMAN IMMUNODEFICIENCY VIRUS PROTEASE EXPRESSED IN ESCHERICHIA-COLI EXHIBITS AUTOPROCESSING AND SPECIFIC MATURATION OF THE GAG PRECURSOR
    DEBOUCK, C
    GORNIAK, JG
    STRICKLER, JE
    MEEK, TD
    METCALF, BW
    ROSENBERG, M
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1987, 84 (24) : 8903 - 8906
  • [7] FREQUENT DETECTION AND ISOLATION OF CYTOPATHIC RETROVIRUSES (HTLV-III) FROM PATIENTS WITH AIDS AND AT RISK FOR AIDS
    GALLO, RC
    SALAHUDDIN, SZ
    POPOVIC, M
    SHEARER, GM
    KAPLAN, M
    HAYNES, BF
    PALKER, TJ
    REDFIELD, R
    OLESKE, J
    SAFAI, B
    WHITE, G
    FOSTER, P
    MARKHAM, PD
    [J]. SCIENCE, 1984, 224 (4648) : 500 - 503
  • [8] GIAM CZ, 1988, J BIOL CHEM, V263, P14617
  • [9] GUAN C, 1988, GENE, V67, P21
  • [10] ACTIVE HUMAN IMMUNODEFICIENCY VIRUS PROTEASE IS REQUIRED FOR VIRAL INFECTIVITY
    KOHL, NE
    EMINI, EA
    SCHLEIF, WA
    DAVIS, LJ
    HEIMBACH, JC
    DIXON, RAF
    SCOLNICK, EM
    SIGAL, IS
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1988, 85 (13) : 4686 - 4690